Subcutaneous Daratumumab for Light Chain Amyloidosis: Efstathios Kastritis, MD

Recently, the FDA approved subcutaneous daratumumab in combination with bortezomib/cyclophosphamide/dexamethasone (VCd) for the treatment of patients with newly diagnosed amyloid light chain (AL) amyloidosis. In this interview, Efstathios Kastritis, MD, Associate Professor of Clinical Therapeutics at the National and Kapodistrian University of Athens and senior author of ANDROMEDA (NCT03201965), the study on which the approval was based, discusses the challenges of treating patients with AL...
Continue reading

Kohei Shitara, MD: Fam-Trastuzumab Deruxtecan-Nxki for Gastric Cancer

Fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo) has recently been FDA approved for the treatment of adult patients with locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal adenocarcinoma previously treated with a trastuzumab-based regimen. In this interview with i3 Health, Kohei Shitara, MD, Chief of the Department of Gastrointestinal Oncology at the National Cancer Center Hospital East in Kashiwa, Japan, and lead investigator of the phase 3 DESTINY-Gastric01 trial, on which the approval was based, shares his insights on this approval, on the challenges of treating this patient population, and on the future of treatment for patients with gastric or gastroesophageal adenocarcinoma.

Continue reading

Understanding and Reducing Regional Variation in Prostate Cancer Surveillance: Samuel L. Washington III, MD, MAS

In patients with low-risk prostate cancer, the use of an active surveillance approach is significantly impacted by geographic location, according to a study recently published in JAMA Network Open. In this interview with i3 Health, Samuel L. Washington III, MD, MAS, Assistant Professor of Urology at the University of California San Francisco and the study's lead author, discusses the significance of these results and suggests ways to reduce variation in the use of active surveillance, thereby op...
Continue reading

Neal Shore, MD, FACS: Relugolix Approval for Advanced Prostate Cancer

Relugolix (OrgovyxTM, Myovant Sciences) was recently FDA approved as the first oral hormone therapy for patients with advanced prostate cancer. In this interview, Neal Shore, MD, FACS, Medical Director of the Carolina Urologic Research Center and lead investigator of the HERO trial, on which the approval was based, speaks with i3 Health about the approval's significance and the future of treatment for patients with this disease. Can you comment on the significance of the approval of relugolix fo...
Continue reading

Roy Herbst, MD, PhD: Adjuvant Osimertinib for EGFR-Mutated Non-Small Cell Lung Cancer

Recently, the FDA approved osimertinib (Tagrisso®, AstraZeneca) as the first adjuvant therapy for patients with surgically resected early-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. In this interview, Roy Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and lead investigator of the ADAURA trial, on which the approval was based, speaks with i3 Health about the significance of the approval of osimertinib for this patient populati...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.